Bacil Pharma Ltd Stock Price Today (NSE: BACPHAR)
Fundamental Score
Bacil Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bacil Pharma Ltd share price today is ₹47.73, down 1.10% on NSE/BSE as of 30 March 2026. Bacil Pharma Ltd (BACPHAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹59.78 (Cr). The 52-week high for BACPHAR share price is ₹51.90 and the 52-week low is ₹26.69. At a P/E ratio of 93.40x, BACPHAR is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -0.98% and a debt-to-equity ratio of 0.00.
Bacil Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Bacil Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Bacil Pharma Share Price: A ROCE-Focused Analysis
The pharmaceutical industry is currently navigating a landscape shaped by increased R&D costs and stringent regulatory approvals, demanding superior capital efficiency. This analysis focuses on Bacil Pharma share price, currently trading at ₹37.029999, and its Return on Capital Employed (ROCE) performance. The company’s current PE ratio stands at a high 93.4, suggesting investor optimism, yet this needs to be critically assessed in light of its profitability.
A critical metric for evaluating any company's long-term prospects is ROCE. Bacil Pharma Ltd's ROCE stands at -0.97%. This negative figure indicates that the company is currently destroying value from its capital employed. This is a significant concern, as a consistently low or negative ROCE can erode shareholder value over time and hinder future growth opportunities. This poor performance directly impacts the company's "moat," or competitive advantage. A strong moat relies on efficient capital allocation and a healthy return on invested capital, both of which are currently lacking in Bacil Pharma's financial profile.
When considering sector peers, the disparity becomes even more apparent. While we aren't diving into detailed comparisons here, it's important to consider how Bacil Pharma stacks up against companies like
Mankind Pharma Ltd. Even without specific figures, differences in ROCE often point to crucial distinctions in management quality and operational efficiency. For example, if Mankind Pharma Ltd exhibits a significantly higher ROCE, it could indicate superior capital allocation strategies, better cost management, or a more effective product pipeline. Further research could contrast Bacil Pharma Ltd with peers Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd as well.In conclusion, the elevated PE ratio of Bacil Pharma, paired with a negative ROCE, warrants caution. While a high PE might indicate future growth expectations, the negative ROCE suggests the company is struggling to generate profits from its invested capital. Potential investors should carefully examine the underlying drivers of this underperformance and assess the company's strategies for improving its capital efficiency. It's crucial to understand how management intends to address the ROCE deficiency and create long-term sustainable value.
Disclaimer: This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra. It is for informational purposes only and does not constitute financial advice. This analysis offers observations based on publicly available data and does not provide any buy or sell recommendations for Bacil Pharma shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bacil Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BACPHAR across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-0.98%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.97%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 93.40x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-97.92%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (2.13% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-4.16 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.08%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Bacil Pharma Ltd Financial Statements
Comprehensive financial data for Bacil Pharma Ltd including income statement, balance sheet and cash flow
About BACPHAR (Bacil Pharma Ltd)
Bacil Pharma Ltd is a dynamic pharmaceutical company rooted in the bustling metropolis of Mumbai, India. Established in 1987, BACPHAR has steadily grown into a significant player i...n the Indian pharmaceutical landscape. With a keen focus on meeting the diverse healthcare needs of the nation, they are dedicated to providing high-quality, affordable medicines to improve the lives of people across the country. Driven by a commitment to scientific innovation and ethical business practices, the company operates with a strong sense of social responsibility, ensuring that its products are accessible to all segments of society. They are steadfast in their mission to contribute meaningfully to the healthcare ecosystem in India. BACPHAR's comprehensive product portfolio encompasses a wide range of therapeutic areas, catering to various medical conditions. From commonly prescribed tablets and convenient capsules to specialized injectables and soothing ointments, they offer a solution for many healthcare requirements. The company takes immense pride in adhering to stringent quality control measures at every stage of the production process, from sourcing the finest raw materials to employing cutting-edge manufacturing techniques. This commitment to excellence ensures that each medicine that bears the BACPHAR name is safe, effective, and of the highest possible standard. Their dedication to quality has earned them the trust and confidence of healthcare professionals and patients alike. Strategically headquartered in Mumbai, a hub of pharmaceutical activity, BACPHAR benefits from its proximity to key industry resources and talent. This advantageous location enables them to stay at the forefront of pharmaceutical advancements and maintain a competitive edge in the market. Their extensive distribution network spans across India, ensuring that their products reach even the most remote areas of the country. BACPHAR is committed to continuous improvement, constantly investing in research and development to expand its product offerings and adapt to the evolving needs of the healthcare industry. The company remains focused on sustainable growth and creating lasting value for its stakeholders.
Company Details
Key Leadership
BACPHAR Share Price: Frequently Asked Questions
What is the current share price of Bacil Pharma Ltd (BACPHAR)?
As of 30 Mar 2026, 12:07 pm IST, Bacil Pharma Ltd share price is ₹47.73. The BACPHAR stock has a market capitalisation of ₹59.78 (Cr) on NSE/BSE.
Is BACPHAR share price Overvalued or Undervalued?
BACPHAR share price is currently trading at a P/E ratio of 93.40x, compared to the industry average of 31.77x. Based on this relative valuation, the Bacil Pharma Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of BACPHAR share price?
The 52-week high of BACPHAR share price is ₹51.90 and the 52-week low is ₹26.69. These values are updated daily from NSE/BSE price data.
What factors affect the Bacil Pharma Ltd share price?
Key factors influencing BACPHAR share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Bacil Pharma Ltd a good stock for long-term investment?
Bacil Pharma Ltd shows a 5-year Profit Growth of N/A% and an ROE of -0.98%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in BACPHAR shares.
How does Bacil Pharma Ltd compare with its industry peers?
Bacil Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare BACPHAR share price P/E of 93.40x and ROE of -0.98% against the industry averages to determine competitive standing.
What is the P/E ratio of BACPHAR and what does it mean?
BACPHAR share price has a P/E ratio of 93.40x compared to the industry average of 31.77x. Investors pay ₹93 for every ₹1 of annual earnings.
How is BACPHAR performing according to Bull Run's analysis?
BACPHAR has a Bull Run fundamental score of 0.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BACPHAR belong to?
BACPHAR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Bacil Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for BACPHAR?
BACPHAR has an ROE of -0.98%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Bacil Pharma Ltd generates profits from shareholders capital.
How is BACPHAR debt-to-equity ratio and what does it indicate?
BACPHAR has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is BACPHAR dividend yield and is it a good dividend stock?
BACPHAR offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Bacil Pharma Ltd shares.
How has BACPHAR share price grown over the past 5 years?
BACPHAR has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth 2.13%.
What is the promoter holding in BACPHAR and why does it matter?
Promoters hold 0.08% of BACPHAR shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Bacil Pharma Ltd.
What is BACPHAR market capitalisation category?
BACPHAR has a market capitalisation of ₹60 crores, placing it in the Small-cap category.
How volatile is BACPHAR stock?
BACPHAR has a beta of N/A. A beta > 1 suggests the Bacil Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BACPHAR operating profit margin trend?
BACPHAR has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is BACPHAR quarterly performance?
Recent quarterly performance shows Bacil Pharma Ltd YoY Sales Growth of N/A% and YoY Profit Growth of -97.92%.
What is the institutional holding pattern in BACPHAR?
BACPHAR has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Bacil Pharma Ltd stock.